LGR5 and neoplasm: Under these treatments, the tumor numbers significantly increased (Lgr5/Apc: 101.2 ± 9.6; Lgr5/Arf1/Apc: 53.1 ± 7.7; ARL/Lgr5/Arf1/Apc: 50.2 ± 10.6; TLR4i/Lgr5/Arf1/Apc: 69.2 ± 11.7; OxATP/Lgr5/Arf1/Apc: 80.6 ± 10.5; OxATP/Lgr5/Arf1/Apc: 82.6 ± 7.0), and the mouse lifespan decreased, while the overall body weight did not change significantly, compared with mice without inhibitor treatment (Fig. 6b, c, and Supplementary Fig. 9a).